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to the LAC arm who were converted to open colectomy were
included in the LAC group in the analysis. RESULTS: Among
855 patients, length of stay (mean: 5.5 vs. 6.7 days) was signiﬁ-
cantly shorter, while operating time was signiﬁcantly longer
(mean: 166 vs. 109 minutes) in the LAC arm. More costly OR
supplies were used in the LAC arm. Resource use was otherwise
similar between arms. The incremental costs were either mod-
estly higher in the LAC arm, $2,454 (95% CI $1,421–$3,485,
2007 US $) (C), or not statistically different, -$62 (95% CI
-$1,759–$1,608) (A) depending on the source of unit costs.
CONCLUSIONS: Economically, the choice between LAC and
OC consists of a tradeoff between higher operative costs and
shorter length of stay. The direction and magnitude of the net
effect depends on the cost inputs from a given institution, with
LAC relatively less expensive in institutions with higher ″hotel″
costs and less costly operative supplies. Future research should
focus on structured peri- and post-operative care to further opti-
mize the care and costs associated with LAC.
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OBJECTIVES:Capecitabine (Xeloda) is an effective alternative to
treat metastatic colorectal cancer (mCRC) patients. This study
compares the costs of capacetabine and UFT/Leucovorin (UFT/
LV) in ﬁrst line therapy for patients with mCRC in Brazil.
METHODS: An analytic-decision model for projecting costs of
treating mCRC in Brazil was developed considering local guide-
lines, to compare costs of capecitabine (2500 mg/m2/day, d1-d14;
21 days-cycle) and UFT/LV (300 mg/m2/day of UFT, d1-d28; 35
days-cycle; 70mg of LV per day), under the payer perspective. The
time horizon of this analysis was 3.5-months, based on the
progression free survival (PFS) of UFT/LV showed in Douillard,
et al 2002 trial. In the absence of head-to-head trials, the same
efﬁcacy, in terms of PFS, was assumed for capecitabine and
UFT/LV. The safety proﬁles were obtained from Twelves, et al
2001 and Douillard, et al 2002. A panel of Brazilian specialists
was conducted to identify the local practices for treating adverse
events (AE). Costing was conducted based on public lists. For the
base case scenario a 1,7 m2 body surface patient was considered.
One-way sensitivity analysis was conducted to check the robust-
ness of the results. RESULTS: The total treatment cost of capecit-
abine is lower than UFT/LV: R$11,908 for capecitabine vs
R$19,417 for UFT/LV. Capecitabine has a lower acquisition cost
(R$3,205/month) than the UFT/LV scheme (R$4,457/month).
Capecitabine shows a better safety proﬁle thus costs for AE
management are lower thanUFT/LV (R$196 for CAP vs. R$1,089
forUFT/LV).CONCLUSIONS: Findings suggest capecitabine as a
cost-saving therapy under the payers’ perspective in Brazil. Total
savings could reach R$7,509 for a 3.5 month-period treatment.
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OBJECTIVES: An economic analysis was undertaken alongside
a trial evaluating chemotherapy with FOLFOX6: (5Fluouracil/
Leucovorin/Oxaliplatin) versus XELOX: (Capecitabine/
Oxaliplatin) as an adjuvant postoperative therapy for high risk
colorectal cancer patients. METHODS: In the absence of sur-
vival difference, a cost-minimisation analysis was undertaken.
Individual patient data (n = 169) were combined with 2008 unit
prices to estimate the cost of chemotherapy, administration,
medical consumables, drugs and laboratory testing. Patient
addresses were used to estimate travelling expenditure and
income data to evaluate productivity losses for those at produc-
tive ages. Raw data were bootstrapped 5000 times to correct for
distortions and to undertake statistical testing. RESULTS: From
a hospital perspective, the mean patient chemotherapy cost was
€8,866 with FOLFOX6 and €9723 with XELOX. Administra-
tion cost was €5,212 and €1,051, erythropoietin €2,787 and
€1,744 and total treatment cost €17,485 and €12,524 respec-
tively. Thus, XELOX reduced overall treatment cost by €4,961
(p  0.01). From a social insurance perspective, the mean che-
motherapy cost was €9,265 with FOLFOX6 and €10,160 with
XELOX. Administration cost was €3,113 and €185, erythropoi-
etin €2,789 and €1,713 and total treatment cost €15,797 and
€12,116 respectively. Thus, XELOX reduced total treatment cost
by €3680 (p  0.01). Mean patient travelling cost was €184 with
FOLFOX6 and 80€ with XELOX, a difference of €104 (p 
0.01). Mean productivity loss was €100 with FOLFOX6 and €31
with XELOX, a difference of €69 (p  0.01). CONCLUSIONS:
Apart from being more convenient for patients, oral chemo-
therapy with Capecitabine(Xeloda) reduces total treatment cost
for the NHS and Insurance Funds, as it reduces drastically the
cost of administration. It also reduces patient travelling time and
cost and productivity loss. Hence, it represents a cost saving and
advantageous approach to the management of operated colorec-
tal cancer patients.
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OBJECTIVES: A cost-minization analysis compared total costs
of XELOX (capecitabine + oxaliplatin) versus FOLFOX-6
(5-FU + folinic acid + oxaliplatin) in the ﬁrst line treatment for
patients with metastatic colorectal cancer (mCRC) in Brazil.
METHODS: An analytic-decision model for projecting costs of
treating mCRC in Brazil was developed considering local guide-
lines and the Brazilian payers’ perspective. According to the
phase III trial of Ducreux et al 2007, we assumed the same
efﬁcacy for XELOX and FOLFOX-6 in terms of progression
free-survival and overall survival. Only direct costs (drugs, IV
administration, physician fees, materials, etc.) were considered
for the chemotherapy and for treating adverse events. The time-
horizon of this analysis was 126 days according to the mean
number of Progression Free Survival found in the Ducreux clini-
cal trial (6 cycles of XELOX and 9 cycles of FOLFOX-6). For the
base case a patient with 1.7 m2 was considered. A Delphi panel
was conducted to identify local practices to manage the adverse
events of each scheme. Discount rate was not necessary because
of the short length of the analysis. RESULTS: Drug acquisition
costs for FOLFOX-6 were higher than XELOX (R$66,433 vs.
R$59,657). XELOX treatment generated a R$15,465 saving per
patient due to a 92% reduction in the number of IV administra-
tions. XELOX also presented a reduction of R$2,121.65 in costs
related to the management of adverse events. A one-way sensi-
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tivity analysis was conducted and conﬁrmed the robustness of the
results. CONCLUSIONS: Findings suggest XELOX as a cost-
saving therapy for the ﬁrst line treatment for mCRC under the
payer perspective in Brazil when compared to FOLFOX-6. when
compared to FOLFOX-6.
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OBJECTIVES: to compare the costs of maintenance therapy with
currently used preparations for hormone-sensitive prostate
cancer with a new leuprorelin 6-month depot (L6) preparation.
METHODS: Patient data were extracted from the IMS Disease
Analyzer observational database. UK patients with a diagnosis of
prostate cancer and three or more prescriptions for goserelin or
leuprorelin were eligible. Individual prescription events were
included if they were for goserelin 28-day depot (G28) or
12-week depot (G84) or for leuprorelin one month or 3-month
depots (L1 and L3). Total cost included drug cost, physician and
nurse visits, prostate speciﬁc antigen (PSA) testing, and payments
for implant administration. The cost of treatment with a newly
available L6 was estimated by varying the daily drug cost, and
assuming resource use equivalent to L3. RESULTS: 118 patients
reported 1262 prescriptions for L3 compared to 600 patients
(8433 prescriptions) for G84, 36 patients (489 prescriptions) for
L1 and 272 patients (2984 prescriptions) for G28. A separate
visit for implant administration was required for 35% of pre-
scriptions with L3, 29% with L1, 41% with G84 and 28% with
G28. PSA testing, although recommended in the UK, occurred
infrequently around the time of prescription (5% of events). The
cost per patient of one year of treatment was £1656 with L3,
£1507 (G84), £1949 (L1) and £2121 (G28). The cost of one year
treatment with L6 if based on the daily drug cost of L3, would be
£1580. Applying the daily drug cost of G28 resulted in £1169,
while applying the G84 daily cost increased it to £1235. Patient
drug costs ranged from 52% of the total cost (G28) to 95% (L6).
CONCLUSIONS: The cost of maintenance therapy for hormone
sensitive prostate cancer is lower when longer-acting prepara-
tions are given, due principally to reductions in non-drug cost
such as GP visit costs.
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OBJECTIVES: To asses the pharmacoeconomic evaluation of
erlotinib used in the second line treatment of metastatic and
developed locoregional non-small lung cancer in the conditions
of the Czech reimbursement policy. We compared costs of
tyrosine-kinase inhibitor erlotinib with the other cytostatic
agents docetaxel and pemetrexed recommended according to
Czech oncological guidelines. METHODS: In the absence of
head to head studies we used data based on clinical trials com-
paring docetaxel and pemetrexed (JMEI) and BR21 study com-
paring erlotinib and placebo. We conducted cost-minimization
analysis from the perspective of the payer. We calculated costs
of drugs, administration, monitoring, premedication, transport
of patients and managment the hematologic toxicities. Prices of
drugs were based on the list of reimbursement of drugs provided
by an reimbursement agency (State Institute for Drug Control)
and payments for health intervencies were collected from the
prices of health care published by health insurance companies.
RESULTS: The costs were calculated for four terapeutic cycles
which referred to median number of cycles administered in the
clinical trials and it was in a concordance with the median value
of progression-free survival. The total costs associated with
therapy were €207,238, €131,720 and €320,000 CZK (€8,635,
€5,488 and €13 333) for erlotinib, docetaxel and pemetrexed.
The acquisition cost was 310,720 CZK (€12,429) for pemetr-
exed, 206,565 CZK (€8,263) for erlotinib and 104,832 (€4,193)
for docetaxel. Erlotinib has more favourable tolerability proﬁle
whereas the cost of adverse events in docetaxel arm was 23,388
CZK (€936) and in pemetrexed arm 5,969 CZK (€239). Also the
administration, monitoring and transportation costs of erlotinib
was signiﬁcantly lower than for docetaxel and pemetrexed.
CONCLUSIONS: The less costly alternative in second-line
therapy of metastatic non-small lung cancer was docetaxel
because of lowest acquisition price. Erlotinib has lowest toxicity,
administration and transportation cost. The cost of erlotinib
is partly compensated by the reduction of toxicity and
management/administration costs.
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OBJECTIVES: Current technology does not adequately predict
the prognosis of patients with acute myeloid leukaemia (AML).
Many patients therefore undergo unneeded but costly and toxic
treatment. However, innovative approaches using genomics,
epigenomics and proteomics technology are being developed to
ameliorate this problem. The aim of this study was to estimate
the potential economic and health impact of these technologies
for AML. METHODS: This study was based on a literature
review and expert opinion regarding the epidemiology, clinical
practice and costs relating to AML and its treatment. Data were
subsequently analysed using decision modelling. RESULTS: Con-
ventional methods help to divide patients into three categories:
favourable prognosis (20% of patients, >60% chance of sur-
vival); intermediate prognosis (60%, 30–40%); and poor prog-
nosis (20%, <20%). Improved diagnostics would reduce the
frequency and costs of unneeded treatment (chemotherapy, stem
cell transplantation). Speciﬁcally, it could reassign some interme-
diate prognosis patients to the favourable prognosis category
(approx. 10%) and others to the poor prognosis category
(approx. 20%). Cost-savings could be €10,000–15,000 per
patient assuming average costs of €100,000. Avoidance of unnec-
essary therapy would also reduce frequencies of side-effects.
While better diagnostics would also result in some extra costs
because of treating patients more intensively, these treatments
would also lead to health gain. Given current diagnostic costs of
€1500–5000 per patient and the high volume of tests, the cost
reduction achievable by improving AML diagnostics would save
millions of euros per year. CONCLUSIONS: Improved AML
diagnostics would reduce some diagnosis, prognosis, and treat-
ment costs. Any increased treatment costs would be coupled with
health gain. In addition, rapid testing would reduce the time
needed to develop a treatment plan and may thereby improve
prognosis.
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